Keywords: USA, FDA, Novartis, Exjade, Roche, Biogen, Rituxan, Leukemia, CLL
US FDA warns on renal, hepatic and gastro problems with Novartis’ Exjade; clears Roche/Biogen’s Rituxan for CLL
Article | 19 February 2010
In a web site posting yesterday, the US Food and Drug Administration notified health care professionals about recent changes in the Prescribing Information (PI) for Swiss drug major Novartis' Exjade (deferasirox), indicated for the treatment of chronic iron overload due to blood transfusions in patients two years of age and older. New language was added to the Contraindications, Warnings and Precautions and Drug Interactions sections of the PI, including a Boxed Warning, that the product may cause:
• Enjoying this article? To continue reading you need to login, take a FREE trial or subscribe.
FREE unlimited, no obligation access to The Pharma Letter website for 30 days, normally worth £60!
Sign up in less than 60 seconds...no payment needed
Want to read the full article?
Take a 30 day FREE Trial worth £60
Take a no obligations 30 day trial.
Only one trial per user. Find out more details
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Ono Pharma buys Japanese rights to two cancer drugs in $340 million deal with Onyx
- GlaxoSmithKline sells Croatian research center to Galapagos, names new CFO and enters supply deal with Lonza; EMEA update on Avandia and Pandemrix
- Wyeth/Pfizer accused of using ghostwritten articles to overstate benefits of HRT
- China’s liver cancer drug market forecast to nearly triple to $144 million in 2014
- International sales rep quality survey views BRIC markets
